The current published clinical literature on angiogenic gene therapy for the treatment of myocardial ischemia does not include a single randomized, placebo-controlled trial. Based on current clinical literature, it is an unproven therapy. Successful animal studies combined with published reports of good outcomes in patients enrolled in uncontrolled trials has led to the expectation that angiogenic gene therapy will ultimately become a clinical reality. The next important landmark in the field will be the publication of data showing a favorable effect of angiogenic gene transfer in placebo-controlled, blinded clinical trials.
Introduction
disease, whether the method of delivery was thoracotomy and intramuscular injection into heart muscle (many), Studies exploring the efficacy and safety of angiogenic nonsurgical intracoronary delivery (few), or injection into gene therapy for the treatment of heart disease using the pericardial space (one). animal models have appeared with increasing frequency
We divide the review into four sections -intramuscular since first reported in 1996 [1] and preliminary uncontrolinjection of adenovirus vectors; intramuscular injection of led clinical trials recently have been published. For extenplasmid DNA; injection of adenovirus into the pericardial sively referenced reviews of angiogenesis the reader need space; and intracoronary delivery of adenovirus. Within not look far -such reviews recently have been prolifereach section we divide the papers into those performed in ating. The current review is, by design, more limited in animal models of heart diseases and clinical trials. Within scope. Specifically, we will (with a single exception) the subgroups we generally have reviewed papers in examine peer-reviewed original publications (to October chronological order from the earliest published papers to 2000) regarding angiogenic gene transfer in experimental the most recent. When appropriate we have included or clinical heart disease. The publications that fulfill these comments regarding strengths and weaknesses of each criteria are few in number. Abstracts are not reviewed.
publication. Because of the absence of published placebo-controlled Both authors have ties to Collateral Therapeutics, Inrandomized clinical studies, we decided to review all trials corporated (CTI) a San Diego biotechnology company that met the above criteria regardless of whether the focused on nonsurgical treatment of cardiovascular disstudies included appropriate controls. Obviously placeboeases using gene transfer. Dr. McKirnan, who worked with controlled trials will be required before definitive concluanimal models of cardiovascular diseases at the University sions can be drawn. We have reviewed all studies of of California San Diego (UCSD) for over 20 years, is now angiogenic gene transfer in experimental or clinical heart Associate Director of Research at CTI. Dr. Hammond, a Professor at UCSD, the scientific founder of CTI serves as a consultant and has a proprietary interest in the company.
These associations were disclosed when the editors asked A second paper, also from the same group, used the that a review be written, a request that was initially porcine ameroid model of stress-induced myocardial isdeclined. However, the editors desired participation despite chemia to determine what toxic effects might result from these associations. We have maintained a critical spirit intramyocardial injection of Ad. VEGF-121 [4] . Twentythroughout the review and have attempted to be fair and one days after left circumflex ameroid placement a second impartial. We are hopeful that our colleagues will pardon thoracotomy was performed and ten sites in the left our critical comments and that we have been equally circumflex perfusion bed were injected. Doses per in- 8 9 critical of the few papers coming from our own laboratory. jection site were 10 and 10 pfu. In addition, replication We apologize if we failed to review any studies that competent adenovirus and replication incompetent adeno-9 fulfilled criteria for review. virus encoding no transgene were also injected (10 pfu per site, ten sites). It should be pointed out that replication competent adenovirus would not likely replicate in porcine 2. Intramyocardial injection of adenovirus using cells as the vector used was a human adenovirus. Echothoracotomy cardiographic assessment, survival, blood analysis, and myocardial and liver histology were examined 3 and 28 2.1. Animal studies days after vector administration. Inflammation and necrosis (described as minimal) were observed in hearts of animals A report of the potential usefulness of direct inthat had received Ad. VEGF-121 gene transfer, but livers tramyocardial injection of an adenovirus encoding an were normal. The Ad. VEGF-121 treated animals also angiogenic gene in the setting of experimentally induced showed an elevation in white blood cell count 3 days after myocardial ischemia was contained in a paper by Rosentreatment (vs. other groups) that was mild and transient. gart and Crystal and colleagues at Cornell [2] . They used
The echocardiograms were apparently obtained only to the porcine ameroid model of stress-induced regional determine if there was an adverse effect of vector adminismyocardial ischemia to determine whether intramyocardial tration on basal regional function (no deleterious effects injection of an adenovirus encoding vascular endothelial were seen) -no data regarding regional myocardial growth factor-121 (Ad. VEGF-121) would reduce stressfunction during stress were reported. The myocardial induced regional myocardial ischemia. Regional function inflammation and necrosis observed, while mild, was (echocardiography) and perfusion (radionuclide imaging) statistically significant and dose-related, with increased 9 were assessed 3 weeks after proximal left circumflex amounts in the animals that had received 10 pfu per site. ameroid placement. Then, at a second thoracotomy, This amount of adenovirus is 75% less than the dose used Ad. VEGF-121 or an empty adenovirus vector was injected that was associated with marked inflammation reported by by needle insertion into the wall of the heart -ten French et al. [3] injections in the left circumflex perfusion bed each consistDeparting for the moment from the porcine ameroid 8 ing of 10 plaque forming units (pfu) -and studies of model of stress-induced reversible myocardial ischemia, regional function and perfusion were repeated 4 weeks what effect might angiogenic gene transfer have in the later. The relationship between virus particle number (vp) setting of acute coronary occlusion? Studies from Capogand pfu (a measure of infectivity) is dependent on the rossi's group at the National Institutes of Health tested two specific adenovirus and the assays used, but generally is hypotheses -first, that angiogenic gene transfer results in around 100 vp per 1 pfu. Therefore, this amount of angiogenesis even when ischemia is not present, and 8 1 0 adenovirus (10 pfu) would be roughly comparable to 10 second, that subsequent acute coronary artery occlusion is vp. Both regional function and perfusion during stress associated with a reduced bed at risk after angiogenic gene were improved in Ad. VEGF-121 treated animals.
transfer [5] . Rabbits underwent thoracotomy and in- 9 This study used the best animal model of regional tramyocardial injection of 10 pfu adenovirus encoding stress-induced myocardial ischemia and employed suitable lacZ (control) or acidic fibroblast growth factor (aFGF, methods to assess regional function and perfusion. It is also known as FGF-1) with an engineered signal sequence impressive that the degree of gene transfer conferred by to promote extracellular secretion of the transgene protein. such relatively low amounts of adenovirus resulted in such
The adenovirus vector was injected in the myocardium improvements. A paper examining intramuscular injection adjacent to the coronary artery that would, 12 days later, of adenovirus in porcine myocardium found limited be occluded and the size of the perfusion bed assessed. amount of reporter gene activity seen predominantly They found a 50% reduction in the perfusion bed at risk adjacent to the needle tract [3] . Although the method of and evidence for angiogenesis and vasculogenesis in hearts gene transfer used by Rosengart, Crystal and colleagues of animals that had received Ad.FGF-1 gene transfer. required thoracotomy, the results were impressive. It is not Specifically, there was a two-fold increase in lengthclear that the acquisition of data was blinded, an important density of intramural arterioles and a 17% increase in the factor to increase the value of echocardiographic studies.
capillary network. However, data analyses were conducted in a blinded
The study demonstrates the potential usefulness of manner.
myocardial FGF overexpression, however, the model is not 9 directly applicable to clinical settings. That is, it is unlikely B received a dose of 4310 vp. Because this was a Phase that thoracotomy and intramyocardial gene transfer of 1 clinical trial, the principal end-points were related to Ad.FGF-1 would be considered in anticipation of myocarsafety. However, also reported were symptoms of angina, dial infarction. Even so, this was a compelling study that exercise treadmill testing, and regional perfusion and adds to the body of experimental data indicating that function assessed by nuclear imaging. overexpression of FGF can have a favorable impact in Three of fifteen patients in Group A died (20%). Group experimental models of coronary artery disease. The B patients were all alive at a mean follow-up of nearly 6 methods used to assess angiogenesis and vasculogenesis months. Angina class scores improved in all patients in are superior to most of the studies so far reported in the Group A, expected sequelae of thoracotomy and CABG field of therapeutic myocardial angiogenesis in that they surgery. All patients in Group B reported reduced angina, included appropriate controls, used perfusion-fixed sambut a statistical analysis was not performed. Coronary ples, and included a two-dimensional analysis. In addition, angiograms, read by three blinded reviewers, exhibited these studies were blinded, a critical element because trends toward improvement for both Rentrop scores and microscopic assessment of angiogenesis is subject to collateral scores in both groups A and B, but statistically interpreter bias.
significant improvements were not obtained and no conKornowski and colleagues from the Epstein laboratory trols were included. Radionuclide perfusion imaging (with at Washington Medical Center used the porcine ameroid adenosine infusion) revealed no improvement in relative model of regional stress-induced myocardial ischemia and blood flow in the area of vector administration 30 days normal pigs to evaluate transendocardial delivery of after gene transfer in either group. However, trends for Ad. VEGF-121 [6] . Using an electromagnetic-based catheimprovement in wall motion during stress were reported ter guidance system, recombinant adenovirus encoding for both groups. Group A patients showed no improvement either lacZ or Ad. VEGF-121, injected at two to six sites at in treadmill exercise 30 days after gene transfer, while 10 a dose of 1310 virus particles (vp) per site, were trends for improvement in exercise duration, rate pressure delivered through a retractable needle without product and ST segment / heart rate slope were reported for thoracotomy. Discrete injection sites exhibited VEGF1-121 group B. expression comparable to that obtained by transepicardial
The failure of both Group A and Group B patients to Ad. VEGF-121 gene transfer at thoracotomy. Transgene show improved exercise duration despite reduction in expression was mainly adjacent to the site of injection, and angina deserves comment. Many would argue that while 5-10% of injections showed no detectable gene transfer, the placebo effect affects treadmill performance, it might perhaps due to systemic delivery of the vector. The study affect symptoms even more. In addition, since examiners showed that the approach could be used to obtain gene collecting data regarding angina frequency were not transfer. However, there were no data regarding histologiblinded, the acquisition of data itself may have been cal changes in the heart, regional myocardial perfusion and biased. Indeed, the major limitation of this study is the function, or angiogenesis.
absence of control subjects. Conclusions cannot be drawn from the study with respect to proof of concept because of 2.2. Clinical trials this shortcoming. This criticism applies also to the studies examining angiographic collateral flow. Those analyzing A clinical trial of patients undergoing thoracotomy and the data were susceptible to bias by knowing that all direct intramyocardial needle injection of an angiogenic patients received gene transfer. A blinded study could gene were reported by the Rosengart and Crystal group [7] .
potentially be achieved by catheter-based methods of gene Direct myocardial injections of Ad. VEGF-121 were adtransfer not requiring thoracotomy, thereby also circumministered to patients that were undergoing coronary artery venting the confounding influence of concomitant bypass graft (CABG) surgery (Group A, n521) and to thoracotomy and CABG surgery. A trial of this nature is patients as sole therapy via a minimally invasive currently underway. thoracotomy (Group B, n56). Patients with demonstrable reversible myocardial ischemia were enrolled. In patients that were to receive gene transfer in conjunction with 3. Intramuscular injection of plasmid DNA CABG surgery, entry criteria included a left ventricular ejection fraction $25% and at least one bypassable vessel.
3.1. Animal studies Group B patients (gene transfer as sole therapy) were required to have a left ventricular ejection fraction $30%
We will now examine the literature regarding the use of and be unsuitable for traditional revascularization.
plasmid vectors encoding angiogenic genes as a means to A fixed volume (100 ml) containing AdVEGF-121 was treat heart disease. Drs. Losordo, Symes and Isner of St. injected in equal amounts in ten sites in a region of Elizabeth's Hospital in Boston have conducted the majorireversible ischemia. Five dose groups containing three ty of these studies. While not an example of plasmid gene transfer, it is VEGF-165 (ph. VEGF-165) would increase regional fitting to discuss a paper from Blau's Stanford group here. myocardial blood flow [8] . Studies of ischemia were They injected murine myoblasts expressing a murine limited to microsphere assessment of regional blood flow VEGF analogous to human VEGF-165 into the hearts of at rest and during adenosine infusion. Gene transfer was otherwise normal but immunodeficient mice [10] . Fifteen achieved by minimally invasive thoracotomy and needle days later five of eleven animals had died (no animals insertion into the wall of the heart in which four injections receiving similar implants of myoblasts expressing lacZ were made, delivering a total of 200 mg of plasmid in a had died). Surviving VEGF-myoblast-treated animals volume of 2.0 ml (0.5 ml per injection site). Injections showed intramyocardial tumors resembling hemangiomas were performed 3-4 weeks after ameroid placement, -abnormalities not seen in the control group. The models following initial determination of basal and adenosineemployed by the Kloner and Blau groups may not hold stimulated regional myocardial blood flow (colored micromuch fidelity with the proposed use of VEGF in clinical spheres). Control animals received a plasmid vector encodsettings, but their findings are consistent and bothersome. ing lacZ in the same quantities.
The angiogenic potential of human hepatocyte growth The studies demonstrated the feasibility of using factor (HGF) gene transfer was recently studies in normal thoracotomy to administer the plasmid to the heart, and and infarcted myocardium of rats by Aoki and colleagues also showed increases in plasma VEGF. The studies of at Osaka University Medical School [11] . HGF or control regional myocardial blood flow were not ideal: the studies vectors were injected into rat heart at thoracotomy -the were conducted in anesthetized animals where differences hemagglutinating virus of Japan (HJV)-liposome-plasmid in level of anesthesia could affect heart function and blood vector was used. Transfection of the HGF gene resulted in flow independently of the effect of the injected gene. In increased immunoreactive HGF and PCNA-positive endoaddition, the myocardial blood flow induced by a suboptithelial cells compared to control vector. HGF gene transmal dose of adenosine (6 mg total i.v.) was less than 50% fer, in both normal and infarcted myocardium, activated of maximal. Even so, the authors were able to demonstrate the angiogenic transcription factor, ets. Reduced HGF increased left circumflex blood flow during adenosine concentration in infarcted heart increased to normal levels infusion after gene transfer as compared to before gene 4 days after HGF gene transfer. Angiogenesis was assessed transfer. The control group, subjected to a similar protocol, by light microscopic analysis of heart samples following did not show such changes. When one considers that the perfusion-fixation. In both normal and infarcted rat hearts, actual degree of gene transfer with this method is substan-HGF-treated animals exhibited greater numbers of vessels tially less than that achieved with other vectors and routes per section than animals that had received injections of of delivery, the results are truly impressive and indicate control vector. Surface myocardial blood flow was asthat small amounts of transgene protein can have physiosessed by laser Doppler at thoracotomy, and revealed logically meaningful effects.
higher values for HGF-treated normal and infarcted rats Returning to the effects of angiogenic gene transfer in compared to controls. This was an excellent study that the setting of myocardial infarction, Kloner and colleagues documented angiogenesis in a blinded and controlled at Good Samaritan Hospital in Los Angeles asked whether manner. ph. VEGF-165 injected into the border zone of infarcted rat Transmyocardial laser revascularization (TMR) has been heart would affect regional blood flow [9] . Rats underwent recently promoted as an effective way to treat patients with coronary occlusion of the left coronary artery followed 30 angina. However, little evidence supports its utility in days later by an additional thoracotomy during which improving regional myocardial blood flow in randomized ph. VEGF-165 was injected in the peri-infarct border at one controlled trials. Sayeed-Shah and colleagues in Laurence location and either saline or a control plasmid at another Cohn's laboratory at Harvard Medical School used TMR region of the peri-infarct border in the same heart. The combined with intramyocardial injections of ph. VEGF-165 blood flow was measured (microspheres) 30 days later and in the porcine ameroid model of stress-induced regional hearts examined. myocardial ischemia [12] . They studied six groups of The sites that had been injected with ph. VEGF-165 animals including: ischemic controls, normal pigs, TMR showed angioma formation evident on gross inspectiononly, TMR with injections of a plasmid encoding lacZ control plasmid and saline injected hearts did not show (ph.lacZ), ph. VEGF-165 injections only, and TMR comangioma formation. While the epicardium at the region of bined with ph. VEGF-165 injections. Fifteen to eighteen injection showed increased vascular structures (including TMR sites were created per heart and three intramyocarangiomas), increased myocardial blood flow was not dial injections were made within 4 mm of each TMR site present. In addition, ph. VEGF-165 injection was associated in the region perfused by the left circumflex coronary with increased peri-operative death rate (death within 24 h artery. Each injection contained 100 mg of ph. VEGF-165 of injection). It would be interesting to see whether the or ph.lacZ. Transesophageal echocardiography during same findings would result after gene transfer using a rapid atrial pacing was used to assess wall motion in the different vector, a different isoform of VEGF, or an FGF. ischemic region. They reported increased lacZ expression when plasmid injections were associated with TMR. Two injection procedure as in the previous study. There was no weeks after treatment animals that had received combined control group. treatment with TMR and ph. VEGF-165 injections showed Patients had uneventful postoperative courses. One improved wall motion compared with ischemic controls. patient died 4 months after gene transfer. Plasma VEGF However, data supporting an angiogenic effect were increased at 14 days to a level two-fold over pretreatment limited. The cardiologist analyzing the echocardiographic values and returned to baseline by 3 months. Patients images was blinded, but it is not clear that images were followed for 90 days (n516) all reported decreased angina acquired in a blinded manner. There was inadequate detail and reduced nitroglycerine use. Seven of ten patients of the echocardiographic studies to evaluate the study.
followed for 6 months were free of angina. Radionuclide Sample size (n53 in combined treatment, n55 in ischemic perfusion imaging showed some improvement after treatcontrols) was inadequate to perform statistical analysis, ment. The problem affecting all of the findings of this and no conclusions can be drawn from these data. study is the absence of a control group. These data, therefore, do not provide rigorous demonstration of suc-3.2. Clinical trials cessful angiogenic gene therapy. Finally, an additional study from the same group, Losordo, Isner and colleagues reported on five patients employing similar methods, reports results in thirteen with inoperable coronary artery disease and symptomatic consecutive patients studied with electromechanical mapmyocardial ischemia who underwent minimally invasive ping and perfusion imaging before and after therapy [15] . thoracotomy during which 125 mg of ph. VEGF-165 was
The study found improvements in both parameters. Again, injected into the anterolateral left ventricular free wall in the studies did not include a control group and were not four 2.0-ml injections containing equal aliquots of the blinded. vector [13] . Patients had multivessel coronary artery disease, severe angina refractive to medical therapy, areas of viable but poorly perfused myocardium and left ven-4. Intrapericardial delivery of adenovirus tricular ejection fractions $20%.
Radionuclide imaging was conducted before, 30 and 60 4.1. Animal study days after gene transfer. Perfusion scans showed fewer abnormally perfused segments and decreased segments
In an interesting departure from intramyocardial inwith fixed defects. Selective coronary angiography before jection of vectors, Lazarous, Unger and colleagues at the and 60 days after gene transfer showed increased contrast National Institutes of Health explored the effects on flow (Rentrop score). All five patients reported a reduction collateral vessel development of intrapericardial delivery in angina, and nitroglycerine use was reduced by day 60.
of an adenovirus encoding VEGF-165 (Ad. VEGF-165) These encouraging findings are limited by the small using the ameroid model of ischemia in dogs [16] . Ten sample size and the absence of a control group. It is argued days after ameroid placement, at a time when endogenous 9 that it is unethical to perform minimally invasive collateral formation is incomplete, Ad. VEGF165 (6310 9 thoracotomy without providing treatment. This argument pfu; n59), an adenovirus encoding lacZ (6310 pfu; presupposes that it is appropriate to perform minimally n59) or saline (n59) were injected into the pericardial invasive thoracotomy to treat with an unproven experimenspace through an indwelling catheter placed at the initial tal agent in a manner that precludes the acquisition of thoracotomy. Twenty-eight days later maximal myocardial conclusive data, a concept apparently sanctioned by regblood flow was measured using the microsphere technique. ulatory agencies. A potentially suitable solution to this Gene expression was abundant in pericardium and dilemma would be to change the patient population to epicardium but not evident in the midwall or endocardium. include patients that undergo thoracotomy and CABG VEGF expression was detectable in samples of fluid from surgery, providing gene transfer in a randomized manner in the pericardial space with a peak occurring 3 days after a portion of the patients and not in others. Alternatively, gene transfer with subsequent decline. Plasma VEGF was the injections into the wall of the heart could be performed not increased. Maximal myocardial blood flow was equivawithout surgery, through catheter-based methods, and a lent in all groups and unchanged by VEGF gene transfer. control group included, a study that was recently initiated Thus, despite sustained increased amounts of VEGF under Losordo and Isner's direction.
produced and released into the pericardial space and gene A second paper from this same group appears to be an transfer in pericardium and epicardium, increased myocarextension of the first clinical trial with a larger sample size dial blood flow did not occur. Of note, Ad. VEGF-165 gene [14] . The study population, as before, included patients transfer but not Ad.lacZ gene transfer was associated with with reversible perfusion defects unsuitable for traditional large pericardial effusions, requiring drainage and resulting revascularization. Either 125 mg (n510) or 250 mg (n510) in death due to pericardial tamponade in one animal. The of ph. VEGF-121 was injected directly into the myocardium authors suggested that large pericardial effusions might be via a minimally invasive thoracotomy, following the same a result of the effect of VEGF on permeability.
Intracoronary delivery of recombinant adenovirus
atrial pressure, dilated poorly functioning hearts). Animals that had been treated with Ad.FGF-4 showed improved 5.1. Animal studies regional cardiac function under basal conditions and during dobutamine infusion. FGF-4 gene transfer reduced left Hammond's laboratory at the VA Hospital and UCSD ventricular dimension over the course of the 3-week study. used the porcine ameroid model of stress-induced regional However, no differences in regional perfusion were demyocardial ischemia and performed intracoronary injection tected. The data suggest a protective effect of FGF growth of a recombinant adenovirus expressing a human fibroblast factors against ischemic injury that is consistent with a growth factor (Ad.FGF-5) [1] . The study compared the report in another model of myocardial hypoperfusion [19] . efficacy of intracoronary Ad.FGF5 (n516) to intracoronThere are two limitations to these studies. First, because 11 ary adenovirus encoding lacZ (n57) both at 2310 vp in of limitations of the model, coronary blood flow during left the treatment of already existing stress-induced regional ventricular pacing and regional function could not be myocardial ischemia. measured simultaneously. Thus, it is possible that changes Treatment was associated with mRNA and protein in blood flow associated with Ad.FGF-4 went undetected. expression of the transferred gene in the heart. Two weeks Second, gene transfer was performed prior to the developafter gene transfer, regional abnormalities in stress-induced ment of heart failure to ensure that transgene expression function and perfusion were eradicated (examined by would be substantial when heart failure developed. It transthoracic echocardiography), effects that persisted for remains to be seen whether treatment of already existing at least 12 weeks. Improved function and perfusion were heart failure can also be achieved with this method. associated with evidence of angiogenesis. This report documented, for the first time, successful treatment of 5.2. Clinical trials abnormalities in myocardial blood flow and function following gene transfer.
A Phase 1 / Phase 2 clinical trial of intracoronary adThe major limitation to the study was that while ministration of Ad.FGF-4 was initiated in May 1998 and capillary angiogenesis was documented, evidence for the initial results announced March 2000. Patients with increased numbers of larger caliber vessels was not stable Class II or III angina were enrolled in a placeboreported. In fact, there were data from three animals in controlled (saline) double-blinded and randomized trial of both groups indicating a two-fold increase in vessels . 10 the safety and efficacy of increasing doses of Ad.FGF-4
mm in diameter, suggesting that conduit vessels were (3310 -10 vp) delivered by intracoronary injection substantially increased in animals receiving Ad.FGF-5, but (nonsurgical). The chief end-point was treadmill exercise the sample size was too small to perform meaningful before and 4 and 12 weeks after treatment. Berlex Biostatistical analyses (unpublished data). However, all assciences and Collateral Therapeutics, Incorporated collabopects of the published study, including histological assessrated on the filing of the commercial IND and the conduct ment of vessel number, were performed in a blinded of the trial. Berlex is the US affiliate of Schering, Berlin. manner.
Because the results of the trial have not yet been published Data reported by McKirnan et al., from the same in a peer-reviewed journal, no specific details can be laboratory, examined the efficacy of intracoronary delivery provided in this review. However, preliminary results of of an adenovirus encoding FGF-4 (Ad.FGF-4) in the this trial have provoked planning for more extensive setting of heart failure. It had previously been shown that clinical trials to be conducted in medical centers throughthe pacing-induced model of heart failure was associated out the US and Europe. with reduced myocardial blood flow per beat [17] . Therefore, a randomized, placebo-controlled and blinded study of sixteen pigs instrumented for hemodynamic monitoring 6. Conclusions and implanted with ventricular pacemakers to induce dilated heart failure was conducted [18] . Hemodynamic 6.1. Animal studies measures and left ventricular function (echocardiography) and perfusion (microspheres and contrast echocardiogIt is reasonable to conclude that intracoronary and raphy) were measured and animals then received inintramuscular injection of adenovirus expressing an-12 tracoronary delivery of 10 vp of Ad.FGF-4 (n58) or giogenic genes can favorably affect regional myocardial saline (n58) in divided doses injected into the left anterior function in the setting of myocardial ischemia and heart descending, left circumflex, and right coronary arteries.
failure in animal models, as these studies were conducted Pacing then was begun (HR 220 bpm) to induce heart in blinded and placebo-controlled investigations. It is also failure, and hemodynamic measures and left ventricular possible that plasmid injection of VEGF DNA into heart function and perfusion were assessed again after 2 and 3 muscle increases myocardial blood flow. Gene transfer into weeks of pacing. Animals had evidence of severe heart the pericardial space provided increased levels of VEGF in failure 2-3 weeks after initiation of pacing (increased left the pericardial space, but transgene expression was appar-
